Rosiglitazone Restores Endothelial Dysfunction in a Rat Model of Metabolic Syndrome through PPARγ- and PPARδ-Dependent Phosphorylation of Akt and eNOS

Vascular endothelial dysfunction has been demonstrated in metabolic syndrome (MS). Chronic administration of rosiglitazone ameliorates endothelial dysfunction through PPARγ-mediated metabolic improvements. Recently, studies suggested that single dose of rosiglitazone also has direct vascular effects...

Full description

Bibliographic Details
Main Authors: Zhigang Zhao, Zhidan Luo, Peijian Wang, Jing Sun, Hao Yu, Tingbing Cao, Yinxing Ni, Jing Chen, Zhencheng Yan, Daoyan Liu, Zhiming Zhu
Format: Article
Language:English
Published: Hindawi Limited 2011-01-01
Series:PPAR Research
Online Access:http://dx.doi.org/10.1155/2011/291656

Similar Items